Medicare GLP-1 Coverage: Eligibility Requirements and $50 Monthly Cost Breakdown
Medicare patients with obesity-related conditions may now access GLP-1 medications like Wegovy and Zepbound for as little as $50 per month under updated Part D coverage rules. With up to 14 million Medicare beneficiaries potentially qualifying, understanding the specific eligibility requirements could mean the difference between paying thousands annually or just $600 a year.
What Changed With Medicare GLP-1 Coverage in 2025
For years, Medicare Part D had a standing exclusion on covering weight-loss drugs — full stop. The program would cover GLP-1 medications only when prescribed for type 2 diabetes, not obesity alone. That landscape has shifted meaningfully, though the change comes with important nuances that beneficiaries need to understand before assuming they qualify.
The core shift happened through a combination of congressional action, CMS guidance updates, and the expanded FDA approval of GLP-1 drugs like semaglutide (Wegovy) for cardiovascular risk reduction. When the FDA approved Wegovy specifically to reduce the risk of serious cardiovascular events in adults with obesity or overweight who also have established cardiovascular disease, it opened a new clinical pathway for Medicare coverage — because Medicare can cover drugs approved for conditions other than weight loss alone.
This is a critical distinction. Medicare isn't suddenly covering GLP-1s purely for weight management. The coverage pathway runs through cardiovascular disease, making the specific diagnosis on your medical record the determining factor in whether you qualify.
The $50 Monthly Cost: How the Math Actually Works
The $50 monthly figure comes directly from the Medicare Part D out-of-pocket cap structure that went into effect in 2025 as part of the Inflation Reduction Act's prescription drug provisions. Here's how the cost structure breaks down:
The $2,000 Annual Out-of-Pocket Cap
Starting in 2025, Medicare Part D beneficiaries have a hard cap of $2,000 on annual out-of-pocket prescription drug costs. Once you hit that cap, your covered drugs cost you nothing for the remainder of the year. This is a seismic change for anyone on high-cost specialty medications like GLP-1s, which carried list prices of $900 to $1,400 per month before insurance.
The Medicare Prescription Payment Plan (M3P)
The second piece of the puzzle is the Medicare Prescription Payment Plan, sometimes called M3P, which allows beneficiaries to spread their out-of-pocket costs evenly across the year rather than paying them all upfront. Under this optional program, that $2,000 annual cap gets divided into roughly equal monthly installments — landing many patients at approximately $167 per month.
So where does the $50 figure come in? For low-income beneficiaries who qualify for the Extra Help program (also called the Low Income Subsidy), cost-sharing is dramatically reduced. Depending on income and asset levels, Extra Help enrollees may pay as little as $0 to $11.20 per month for covered drugs in 2025. The $50 figure represents an approximate blended estimate for beneficiaries in certain coverage phases, not a universal number every Medicare patient can expect.
Want to run your specific numbers? Use our GLP-1 cost calculator to estimate what you'd pay based on your Medicare plan and income level.
Who Qualifies: The Specific Eligibility Requirements
The 14 million figure cited by health policy analysts represents the estimated number of Medicare beneficiaries who could meet the clinical criteria for GLP-1 coverage under the cardiovascular indication. But qualifying isn't automatic — you need to meet a specific combination of conditions.
Established Cardiovascular Disease Requirement
This is the non-negotiable threshold. To qualify for Medicare-covered GLP-1 therapy under the current pathway, you must have documented, established cardiovascular disease. That generally means a prior diagnosis of one or more of the following:
- Heart attack (myocardial infarction)
- Stroke or TIA (transient ischemic attack)
- Peripheral arterial disease (PAD)
- Coronary artery disease
- Heart failure (in some clinical contexts)
Simply having cardiovascular risk factors — like high blood pressure or high cholesterol — does not meet this threshold. The disease must be established and documented in your medical records.
BMI and Weight Requirements
In addition to cardiovascular disease, you must have a BMI of 27 or higher. This aligns with the FDA's approval criteria for Wegovy in the cardiovascular risk reduction indication. Patients with a BMI below 27 would not meet the clinical threshold, even if they have cardiovascular disease.
Your Part D Plan Must Cover the Specific Drug
Here's where many beneficiaries get tripped up: Medicare Part D plans are not federally required to cover every GLP-1 drug. Each plan maintains its own formulary, and coverage of Wegovy or Zepbound specifically is not guaranteed across all plans. You'll need to verify that your specific Part D plan includes the medication your doctor prescribes.
The CMS Medicare prescription drug coverage page provides tools to compare Part D plan formularies and find plans that cover specific medications in your area.
What About Obesity Without Cardiovascular Disease?
If you have obesity but no established cardiovascular disease, the current Medicare coverage pathway does not apply. There is active legislative discussion — including proposed bills that would require Medicare to cover anti-obesity medications more broadly — but as of 2025, no such mandate has been enacted. Some Medicare Advantage plans may offer additional obesity medication coverage as a supplemental benefit, so it's worth checking your specific plan details.
How to Verify Your Coverage and Get Started
If you believe you meet the eligibility criteria, here's a practical step-by-step approach to confirming your coverage and accessing the medication.
Step 1: Review Your Medical Records
Pull your medical records and confirm that your cardiovascular disease diagnosis is clearly documented. Vague language or risk factor notation won't be sufficient for coverage approval. Your diagnosis code (ICD-10) matters — your prescribing physician needs to understand which codes support a successful prior authorization.
Step 2: Talk to Your Doctor About Prior Authorization
Most Medicare Part D plans will require prior authorization for GLP-1 medications. Your doctor's office will typically handle this process, but you should proactively ask about it. Prior authorization can take days to weeks, and coverage may be denied on the first attempt. If that happens, you have the right to appeal — and a well-documented appeal with clinical notes supporting the cardiovascular indication often succeeds.
Step 3: Check Your Specific Part D Plan Formulary
Log into your Part D plan's member portal or call the plan's pharmacy benefits line to confirm whether Wegovy (semaglutide) or Zepbound (tirzepatide) appears on the formulary and what tier it's placed on. Tier placement directly affects your cost-sharing amount before you reach the out-of-pocket cap.
Step 4: Enroll in the Medicare Prescription Payment Plan
If your costs are significant, enroll in M3P to spread them out monthly rather than paying large upfront amounts. You can enroll through your Part D plan during open enrollment or after you begin a high-cost medication.
For a personalized cost estimate based on your plan tier and coverage phase, try our Medicare GLP-1 cost calculator to see what your actual monthly expense might look like.
What This Coverage Does Not Include
It's worth being clear about the boundaries of current Medicare GLP-1 coverage to avoid surprises:
- Purely cosmetic weight loss is not covered, and prescribers using that framing will not get prior authorization approved.
- Over-the-counter alternatives or compounded semaglutide are not covered under Medicare Part D, regardless of diagnosis.
- Medicare Part A or Part B do not cover GLP-1 medications in outpatient settings — this is exclusively a Part D benefit.
- Medigap supplemental policies generally do not cover Part D cost-sharing, though this varies by plan type and state.
You can find the official Medicare Part D formulary and benefit explanation framework on the CMS prescription drug coverage general information page.
Frequently Asked Questions About Medicare GLP-1 Coverage
Does Medicare cover Ozempic for weight loss?
Not directly for weight loss. Ozempic (semaglutide) is FDA-approved specifically for type 2 diabetes, and Medicare Part D has long covered it under that indication. If you have type 2 diabetes and your doctor prescribes Ozempic, coverage is generally available. However, for obesity without diabetes and without cardiovascular disease, neither Ozempic nor Wegovy is currently covered under Medicare's standard Part D requirements.
What if my Part D plan denies coverage for a GLP-1 medication?
A denial is not the end of the road. You can request a formal redetermination (first-level appeal) from your Part D plan, and if that fails, escalate to an independent review entity. Many denials are overturned at the appeal stage when clinical documentation — especially the specific cardiovascular diagnosis — is clearly presented. Ask your doctor's office to write a letter of medical necessity supporting the appeal.
Can I switch Part D plans to get better GLP-1 coverage?
Yes, during Medicare's Annual Enrollment Period (October 15 through December 7 each year), you can switch Part D plans. If your current plan doesn't cover Wegovy or Zepbound, or places it on a high-cost tier, comparing plans using the Medicare Plan Finder tool at Medicare.gov may reveal options with more favorable GLP-1 coverage and lower cost-sharing before you hit the annual cap.
Does the $2,000 out-of-pocket cap apply to Medicare Advantage prescription drug plans?
Yes. The $2,000 annual cap applies to all Medicare Part D prescription drug coverage, including the drug benefit embedded in Medicare Advantage (MA-PD) plans. However, the specific formulary, prior authorization requirements, and tier structure vary by plan, so your actual cost path to that cap will differ based on your specific Medicare Advantage plan.